dosi. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I. Physiology and biochemistry. J. Appl. Physiol. 83(2): 550-558, 1997.-Prolonged hyperoxia causes lung injury and respiratory failure secondary to oxidative tissue damage mediated, in part, by the superoxide anion. We hypothesized that aerosol treatment with recombinant human manganese superoxide dismutase (rhMnSOD) would attenuate hyperoxic lung damage in primates. Adult baboons were anesthetized and ventilated with 100% oxygen for 96 h or until death. Six animals were treated with aerosolized rhMnSOD (3 mg · kg 21 · day 21 in divided doses), and six control animals did not receive enzyme therapy. Physiological variables were recorded every 12 h, and ventilation-perfusion ratio relationships were evaluated by using the multiple inert-gas elimination technique. After the experiments, surfactant composition and lung edema were measured. We found that rhMnSOD significantly decreased pulmonary shunt fraction (P , 0.01) and preserved arterial oxygenation (P , 0.01) during hyperoxia. The rhMnSOD increased lung phospholipids, phosphatidylcholine and disaturated phosphatidylcholine, and decreased lung edema in this model. Testing of higher and lower doses of MnSOD (1 and 10 mg·kg 21 · day 21 ) in two other groups of baboons produced variable physiological protection, suggesting a ''window'' of effective dosage. We conclude that aerosolized MnSOD (3 mg·kg 21 · day 21 ) affords significant preservation of pulmonary gas exchange during hyperoxic lung injury. antioxidant enzymes; superoxide dismutase; oxygen; acute respiratory distress syndrome; acute lung injury PROLONGED EXPOSURE to 100% oxygen causes a diffuse lung injury that leads to respiratory failure, similar to the acute respiratory distress syndrome (ARDS). Oxygen toxicity and ARDS involve oxidative stress in the lung. The lung injury is related in part to production of superoxide anion (O 2 2 z), a free radical that can cause biological damage by itself or promote formation of other reactive oxygen species (ROS), including hydrogen peroxide (H 2 O 2 ), peroxynitrite (ONOO 2 ), and hydroxyl radical (z OH).
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Among the primary antioxidant defenses in the lung are enzymes that detoxify reactive oxygen species such as the superoxide dismutases (SODs). Manganese SOD (MnSOD) is one of three SOD isoforms present in mammalian tissues. MnSOD is normally found within mitochondria and constitutes a smaller fraction of pulmonary SOD activity (,20% of the total) than other isoforms of SOD, e.g., copper-zinc SOD (CuZnSOD) (27) . The role of MnSOD in protection from oxidative stress has been demonstrated in studies showing increases in MnSOD mRNA and protein in response to sublethal hyperoxia and other forms of oxidative stress (5, 18, 19) . Additionally, cytokines like interleukin-1 and tumor necrosis factor increase MnSOD expression during the development of oxygen tolerance (22, 23) .
Attempts to protect the lung from oxygen toxicity by using CuZnSOD have had variable success. Most of the studies have required for effectiveness a delivery system such as liposomes or conjugation of the enzyme to polyethylene glycol (1, 3, 4, 24) . MnSOD differs from CuZnSOD because the protein carries a positive charge that may increase its affinity for the plasma membrane when delivered to the cell surface. This characteristic may affect its site of deposition and activity, resulting in more efficacious antioxidant effects in the lungs. Furthermore, the relative importance of different isoforms of SOD in different oxidative injuries is not known.
We have established a primate model of pulmonary oxygen toxicity by exposing baboons to 100% oxygen for 96 h (11, 12) . The baboon is appropriate for testing therapeutic interventions delivered by aerosol because of the similarity of its lung to that of humans. This includes a dichotomous airway-branching pattern so that localization of injury and delivery of drugs should be similar. We hypothesized that augmentation of pulmonary antioxidant defenses by administration of aerosolized MnSOD would protect against pulmonary oxygen toxicity by affording measurable physiological and biochemical protection from this insult. A quantitative morphological study of the lung injury is presented in the accompanying manuscript (28) .
METHODS
Adult male baboons (Papio cynocephalus, Southwest Foundation, San Antonio, TX) were used for the study. The animals were quarantined for at least 4 wk before use. They were determined to be tuberculosis free and were handled in accordance with American Association for the Accreditation of Laboratory Animal Care guidelines. They were fasted overnight before the experiment began and then sedated with intramuscular ketamine (20-25 mg/kg). After orotracheal intubation with a no. 6 endotracheal tube, the animals were ventilated with a volume-cycled ventilator (Puritan-Bennett, Kansas City, KS, model 7200a) at a tidal volume of 12-15 ml/kg, positive end-expiratory pressure of 2.5 cmH 2 O, and a rate sufficient to maintain an arterial PCO 2 (Pa CO2 ) of 35-45 Torr. Peak inspiratory flow was set at 15 l/min. The animals were paralyzed with pancuronium (4-8 mg iv followed by 4 mg iv every 2 h), and sedation was maintained with ketamine (3-10 mg · kg 21 ·h 21 ) and diazepam (0.4-0.8 mg/kg every 2 h) given through a peripheral venous catheter. Ampicillin (1 g) every 6 h intravenously and gentamicin (40 mg) and polymyxin (20,000 units) intratracheally every 4 h were given as prophylaxis against nosocomial pneumonia. A pulmonary artery catheter (5-Fr) was inserted via a femoral incision to monitor central venous, pulmonary arterial, and pulmonary arterial wedge (occlusion) pressures; sample mixed venous blood; and determine cardiac output. Cardiac output was measured by thermodilution (5-ml injectate) performed in triplicate, with the average of three trials used for calculations (Horizon 2000 monitor, Mennen Medical, Clarence, NY). A femoral artery catheter was used to monitor blood pressure and obtain blood samples for arterial blood-gas measurements. Arterial and mixed venous blood PO 2 , PCO 2 , and pH were measured by using a pH/blood-gas analyzer (Instrumentation Laboratory, models 813 and 1304, Lexington, MA). Hemoglobin concentration, oxygen saturation, and oxygen content were obtained by using a CO-oximeter (Instrumentation Laboratory, model 482) programmed for baboon hemoglobin. Systemic arterial, central venous, and pulmonary arterial pressures were measured with Gould TDN-R pressure transducers and displayed on a Horizon 2000 monitor.
Experimental protocol. The study was designed to test the hypothesis that 3 mg · kg 21 · day 21 of aerosolized MnSOD would improve physiological function during pulmonary oxygen toxicity in the baboon. The dose of enzyme was chosen on the basis of preliminary studies in rodents. After completing the untreated and 3 mg · kg 21 · day 21 treatment groups, we evaluated two other doses of enzyme for comparison. Thus four groups of six animals each were studied. One group (control) of six animals was ventilated on 100% oxygen for 96 h or until death. These animals did not receive MnSOD. A second group of animals was ventilated on 100% oxygen for 96 h and received aerosolized 3 mg · kg 21 · day 21 MnSOD in divided dose every 12 h. The third group of animals was ventilated on 100% oxygen for 96 h and received aerosolized 1 mg·kg 21 · day 21 MnSOD in divided dose every 12 h. The final group of animals received 100% oxygen for 96 h and aerosolized 10 mg · kg 21 · day 21 MnSOD in divided dose every 12 h. Treatment was initiated at the onset of hyperoxia.
After the animals were prepared, they were monitored for ,2 h for hemodynamic stability, and baseline cardiovascular, ventilator, and ventilation-perfusion ratio (V A/Q ) measurements were obtained. Maintenance intravenous fluid was begun at 30 ml/h. Heart rate, temperature, arterial blood pressure, pulmonary arterial pressures, fluid balance, and ventilator parameters were recorded every hour. Additionally, every 12 h, arterial and mixed venous blood gases, pulmonary arterial wedge pressure, and cardiac output were recorded. Airway care consisted of endotracheal suctioning, manual sigh breaths, position changes, and chest physiotherapy every 6 h. The animals were killed by KCl injection at 96 h, and autopsy followed immediately. An additional group of six animals was ventilated with air for 96 h under the same conditions. Selected data from this group are included to provide normal reference values. The average weight of the animals in the four experimental groups ranged from 14.4 to 16.2 kg.
MnSOD aerosol and delivery system. Recombinant human MnSOD (rhMnSOD) was obtained from Boehringer-Ingelheim Pharmaceuticals (Ridgefield, CT). Activity was assessed by the cytochrome c reduction assay and found to be 3,100-3,580 U/mg. The drug was delivered via ultrasonic nebulization (De Vilbiss Aerosonic Nebulizer, model 5000B) in series with the inspiratory limb of the ventilator circuit. The concentrations of protein in the aerosol were 1.0, 3.0, and 10 mg/ml, respectively, for the three doses of rhMnSOD. Particle characteristics were defined by using a cascade impactor and an endotracheal tube. These studies revealed a mass median diameter of 2.5-3.0 µm and a geometric SD of 2.5 µm for the aerosol. Typically, each dose of the enzyme was delivered over a 20-to 30-min period. The nebulizer did not alter the activity of the enzyme.
Quantitation of V A/Q distribution. V A/Q distributions were quantified by using the multiple inert-gas elimination technique of Wagner et al. (25) . These measurements were made at 0, 12, 36, 64, 84, and 96 h of hyperoxia. A dilute solution of six inert gases (sulfur hexafluoride, ethane, cyclopropane, enflurane, diethyl ether, and acetone) in normal saline was infused continuously via a peripheral vein at a rate of 2.5-3 ml/min. Duplicate samples of systemic arterial blood, mixed venous blood, and mixed expired gas were collected at least 40 min after the infusion was begun. Each blood sample was equilibrated with an equal volume of nitrogen in a heated water bath (37°C) for at least 40 min. The equilibrated gas and expired samples were analyzed for sulfur hexafluoride by an electron-capture detector and for the other five gases by a flame-ionization detector (Varion Gas Chromatograph, model 3700 and Hewlett-Packard Chromatograph, model 5890, series II). The data were directed to an analog-to-digital converter (Nelson Analytical 900 series interface) and stored on a computer for analysis. The blood-gas partition coefficients of six inert gases also were determined each day. Retention-partition coefficient and excretion-partition coefficient curves were generated by using the technique of enforced smoothing and least squares analysis. These data were then transformed into V A/Q distribution by using a 50-compartment lung model. The shunt was defined as V A/Q ,0.005 and dead space as V A/Q .100. The log(V A/Q ) SD values of perfusion and ventilation (SDq and SDv, respectively) were used as indexes of dispersion of blood flow and ventilation, respectively (10) .
Lung wet-to-dry weight ratios and lavage protein. At the end of the experiments, the animals were killed and autopsied immediately. After the chest was opened, the left mainstem bronchus was ligated, and that lung was removed. Multiple samples were obtained, weighed, and dried in a vacuum oven for 72 h at 60°C to determine wet-to-dry weight ratios. A lobe of this lung was selected arbitrarily and lavaged with iced 0.9% NaCl solution. Protein content in the lavage fluid was measured (14) .
Surfactant biochemistry. Total lipids were extracted from the bronchoalveolar lavage done in a lobe of the left lung at the end of the experiments (7) and separated into neutral and phospholipids (PLs) on silica gel columns and into PL classes by thin-layer chromotography (21) . Disaturated phosphatidylcholine (DSPC) was isolated on neutral alumina columns after osmium tetroxide treatment of total PLs (15). Phosphorus was measured and assumed to be 4% of the PL by weight (2) . Corrections for losses of lipid during processing were measured by adding a trace amount of [ 14 C]dipalmitoyl phosphatidylcholine. Surfactant protein-A enzyme-linked immunosorbent assay was performed as previously described (11) . These studies were performed only in animals receiving oxygen, air, and 3 mg · kg 21 · day 21 MnSOD plus oxygen.
Statistical analysis. Data are presented as means 6 SE. Statistical analysis was performed by using SAS statistical software (SAS Institute, Cary, NC). Repeated-measures data from physiological measurements were analyzed by using linear regression analysis allowing for both fixed and random effects. Because there were missing values due to some animals dying before 96 h, the standard repeated-measures model was employed (26) . Drug effects were compared at the 96 h time point, and slopes (rate of change with time) were also compared among groups. The primary comparison a priori was between the oxygen control group and the 3 mg·kg 21 · day 21 rhMnSOD group by using a P value of 0.05 as significant. After two additional doses of rhMnSOD were added to the experimental protocol, all enzyme doses were compared with the oxygen control group and, in some cases, with each other. Because the comparison of all three MnSOD groups with oxygen was post hoc, we denoted as significant only the P values that reached the 0.05 level after a Bonferroni correction. Surfactant data and wet-to-dry weight ratios for the oxygen control group and the 3 mg · kg 21 · day 21 MnSOD group were compared by using the Student's t-test or the Mann-Whitney test as appropriate. Survival differences were compared by using Kaplan-Meier analysis. Observa- Data are means 6 SE; n 5 6 in each group. rhMnSOD, recombinant human manganese superoxide dismutase; MAP, mean arterial pressure; PAM, mean pulmonary arterial pressure; CO/kg, cardiac output adjusted for body weight; SVR p kg/10, systemic vascular resistance adjusted for body weight divided by 10; PVR p kg, pulmonary vascular resistance adjusted for body weight; Hb, hemoglobin concentration; DO 2 /kg, oxygen delivery adjusted for body weight; V O 2 /kg, oxygen consumption adjusted for body weight; Ext ratio, oxygen extraction ratio (V O 2 /DO 2 ). P values are reported for comparison of drug effects with respect to untreated oxygen-exposed group at 96 h and for a time-by-drug interaction effect (i.e., comparison of slopes). tions from animals not meeting physiological criteria for stopping the experiment were considered censored observations.
RESULTS

Survival.
Five of six animals survived 96 h of exposure to 100% oxygen in the group of untreated animals and in the groups receiving 1 and 10 mg · kg 21 · day 21 of rhMnSOD. The sixth animal in the untreated group died at 84 h from severe hypoxemia. One animal in the 1 mg·kg 21 · day 21 group died abruptly after 72 h without hypoxemia or acidosis. The sixth animal in the 10 mg·kg 21 · day 21 group died after 72 h with severe acidosis (pH 7.08), but it was not hypoxemic. Several animals in these three groups approached physiological criteria at 96 h for stopping the experiment [Pa O2 ,60 Torr on 100% oxygen or mean arterial pressure (MAP) ,60 mmHg]. This included three animals in the untreated group, one in the 1 mg · kg 21 · day 21 group, and two in the 10 mg · kg 21 · day 21 group. All animals receiving 3 mg·kg 21 · day 21 rhMnSOD survived 96 h, showing no sign of impending physiological collapse. The survival difference between the untreated oxygen-exposed animals and those receiving 3 mg · kg 21 · day 21 of rhMnSOD during oxygen exposure approached statistical significance (P 5 0.06).
Hemodynamics. The cardiovascular effects of 96 h of hyperoxia in control and MnSOD-treated animals are reported in Table 1 . In general, 3 mg · kg 21 · day 21 of rhMnSOD tended to minimize the changes in cardiovascular variables. Intravascular volume status and left ventricular end-diastolic pressure as assessed by central venous pressure and pulmonary capillary wedge pressure were maintained within the normal range in all groups during the experiment. Central venous pressure remained between 6 and 8 mmHg and pulmonary capillary wedge pressure between 9 and 12 mmHg. MAP increased slightly in all groups during the first 48 h of hyperoxia. MAP then began to drop between 48 and 60 h in all groups, except in animals receiving 3 mg·kg 21 · day 21 in which a slight decline began at 84 h. Systemic vascular resistance mirrored the MAP profile. Heart rate increased while cardiac output and stroke volume decreased with time in all groups. The smallest change occurred in the 3 mg · kg 21 · day 21 treatment group. Mean pulmonary arterial pressure increased 46% and pulmonary vascular resistance increased 245% in untreated hyperoxia at 96 h but the increases were limited to 10 and 63%, respectively, in the rhMnSOD group receiving 3 mg · kg 21 · day 21 of the enzyme. Hemoglobin concentration decreased by 3-4 g/dl in all groups related to the effects of oxygen and blood withdrawn for studies. The rate of decline in the hemoglobin concentration, however, was significantly slower in all MnSODtreated groups. Oxygen delivery decreased in all groups, but this effect was significantly less in the 3 mg·kg 21 · day 21 rhMnSOD group. Systemic oxygen consumption remained constant. This resulted in an increase in the oxygen extraction ratio and a decrease in mixed venous PO 2 . The extent and rate of decrease in the mixed venous PO 2 were significantly less in all MnSOD-treated groups.
Respiratory variables, V A/Q relationships, and gas exchange. The effects of MnSOD on respiratory variables are reported in Figs.1-3 and Tables 2 and 3 . Pa O 2 progressively decreased with continuous exposure to 100% oxygen. Aerosolized rhMnSOD significantly attenuated the decline in Pa O 2 in all treated groups, as shown in Fig. 1 . Actual values and significance levels are reported in Table 2 . Figures 2 and 3 show the changes in V A/Q relationships during the hyperoxic exposure. The statistical analyses of these changes compared with oxygen are provided in Table 3 . Shunt fraction increased from 1% of cardiac output at baseline to 40% at 84 h in the untreated control group. We were unable to study three animals in this group using the multiple inert-gas elimination technique at 96 h because the animals died or exhibited non-steady-state conditions due to physiological deterioration. The final V A/Q data point represents only three stable surviving animals. Figure 2 shows that the increase in shunt fraction was limited to 10% of the cardiac output at 96 h in the animals treated with 3 mg · kg 21 · day 21 of the enzyme (P 5 0.001). A decrease in shunt fraction was also seen in both of the other treated groups but to a lesser extent. Dead space remained relatively constant in all groups (Fig. 2) . rhMnSOD treatment had inconsistent effects on ventilation-perfusion matching, as seen in Fig. 3 . In the group receiving 3 mg·kg 21 · day 21 , rhMnSOD treatment was associated with the least change in dispersion of perfusion but the most change in dispersion of ventilation. Animals treated with 1 or 10 mg · kg 21 · day 21 of enzyme had ventilation-perfusion relationships similar to untreated animals. Total respiratory system compliance (including the ventilator circuitry, chest wall, and lungs) decreased significantly over time in all groups. Untreated animals showed a 42% decrease in compliance, compared with 32% in animals receiving 3 mg·kg 21 · day 21 of enzyme (P 5 0.12). Animals receiving 1 or 10 mg·kg 21 · day 21 of enzyme had changes in compliance closer to these of the untreated group. Peak airway pressures were 16-17 cmH 2 O in all groups at baseline and increased in the untreated oxygenexposed animals to the 30-32 cmH 2 O range. Airway pressures in animals receiving rhMnSOD at 3 mg·kg 21 · day 21 increased to ,25 cmH 2 O, whereas ani- http://jap.physiology.org/ mals in the other two treatment groups showed slightly greater increases in peak pressures ( Table 2 ). The minute ventilation required to maintain a normal Pa CO 2 increased in all groups but significantly less in animals treated with 3 mg · kg 21 · day 21 of enzyme (P 5 0.01). Five of six baboons treated with 10 mg·kg 21 ·day 21 had a significant acidosis (pH ,7.25) at 96 h or at death. This is in contrast to one of six in the group receiving 1 mg · kg 21 · day 21 , none in animals receiving 3 mg·kg 21 · day 21 , and two in the untreated group. Differences between dosage groups did not reach statistical significance after Bonferroni corrections were applied to the data.
Surfactant analysis. The composition of PLs in the lavage fluid is shown in Table 4 . rhMnSOD treatment at a dose of 3 mg · kg 21 · day 21 attenuated many of the changes in lavage fluid caused by prolonged hyperoxia. Hyperoxia caused a decrease in lavage total PLs, phosphatidylcholine (PC), and DSPC. Treatment with rhMnSOD significantly increased PL, PC, and DSPC, even above values seen with mechanical ventilation alone. Lavage protein increased in hyperoxic lung injury, and this effect was decreased by rhMnSOD treatment, despite nebulizing protein into the lung. The amount of surfactant protein-A in the lavage fluid was not affected significantly by rhMnSOD.
Lung edema. Hyperoxia caused severe lung edema with a wet-to-dry weight ratio of 7.38 6 0.27 in untreated baboons (Table 4) . rhMnSOD significantly decreased lung edema; the wet-to-dry ratio was 5.89 6 0.37 (P 5 0.01), although this value is greater than that after mechanical ventilation alone (4.76 6 0.20). Wet-todry ratio for animals treated with 1 mg · kg 21 · day 21 rhMnSOD was 6.37 6 0.53, and for those treated with 10 mg · kg 21 · day 21 the ratio was 6.48 6 0.74.
DISCUSSION
This study demonstrated significant physiological protection against pulmonary oxygen toxicity by aerosolized rhMnSOD (3 mg · kg 21 · day 21 ) in baboons during prolonged exposure to hyperoxia. MnSOD preserved arterial oxygenation, decreased intrapulmonary shunt fraction, and decreased pulmonary edema, compared with untreated oxygen-exposed animals. MAP was maintained, and trends in other cardiovascular variables suggested less physiological decline. Changes in surfactant composition induced by oxygen were attenuated by treatment with rhMnSOD. Lipid composition moved toward values seen in normal baboons ventilated with air alone. We also found a doseresponse effect with lesser degrees of physiological protection at lower and higher doses of MnSOD, including possible evidence of drug toxicity at high doses.
The improvement in arterial PO 2 observed in the rhMnSOD-treated animals was related primarily to decreased intrapulmonary shunt and, to a lesser degree, improved SDq. The decrease in shunt fraction can be explained in two ways, by improved ventilation or by diversion of blood flow from unventilated to ventilated regions. Our data are most suggestive of improved (or Drug effect comparisons were made at the 96-h time point; n 5 6 animals in each group. Slopes (reflecting a time-by-drug interaction) were also compared. Values are P values computed from linearregression model. SDq, dispersion of perfusion; SDv, dispersion of ventilation; V A/Q , ventilation-perfusion ratio. http://jap.physiology.org/ maintenance of) ventilation as an explanation for the lower intrapulmonary shunt. This explanation is consistent with decreased injury to the alveolar epithelium but not to the endothelium. Although the changes in shunt and SDq also may be caused by effects of the treatment on the pulmonary vasculature, the lack of change in cardiac output between treated and untreated animals, the smaller change in pulmonary vascular resistance in the treated group, and similar intravascular inflammatory changes by morphometry make this mechanism less likely. SDv increased with hyperoxia and then stabilized, an effect that occurs before the inflammatory phase of hyperoxic injury in this species (8) . The higher SDv in the 3 mg · kg 21 · day 21 -treated animals toward the end of the exposure may also reflect alveolar epithelial protection in this group.
The mechanism whereby MnSOD produces its protection against hyperoxic lung injury is presumably due to scavenging of O 2 2 z by the enzyme. The enzyme remains active after aerosolization, and blood levels of MnSOD activity increase in rodents after aerosol therapy. O 2 2 z production by lung tissue has been shown to increase during exposure to hyperoxia (9) . Moreover, various stimuli have been shown to induce SOD activity in association with tolerance to hyperoxia (20, 22, 23) . These findings have supplied the rationale for attempts to decrease lung injury from ROS by exogenous SOD. Results have been varied, but several studies have shown a positive effect when the drug is delivered to the air spaces (1, 3, 24) . In the present study, MnSOD was administered in its native form without the need for derivitization or a liposome-based delivery system as has been required for other isoforms of SOD. A major difference between MnSOD and CuZnSOD is that MnSOD carries a positive charge, whereas CuZnSOD is negatively charged. This may significantly affect the site and extent of deposition of the enzyme and the duration of activity. It also may be the reason that no special delivery strategy was needed for the drug.
Scavenging (18) . Furthermore, if the O 2 2 z reaction with NO z is a significant means for regulation of the biological effects of NO z, the effects on feedback mechanisms related to NO z release may be altered, affecting multiple cell functions, including oxidant production, vascular and airway tone, and cytokine release. These important areas are being investigated in studies at the cellular and organ level. Some of the physiological findings in MnSOD-treated animals, such as decreased pulmonary artery pressures and pulmonary vascular resistance, could be related in part to increased NO z activity.
ROS are produced in hyperoxia intracellularly (e.g., by lung mitochondria) and extracellularly (e.g., by inflammatory cells). ROS usually react biologically at or near their site of production. This is important because attempts to decrease toxicity by scavenging ROS require the drug to be delivered to the sites of ROS production. Although our study did not directly assess the site of production of ROS, MnSOD was delivered to the airways and alveolar spaces. Other work (6) and the accompanying study (28) demonstrate MnSOD deposition along epithelial surfaces, in the airways and in alveolar macrophages, without evidence for significant epithelial cell uptake of the compound. This contrasts with studies that demonstrate oxygen tolerance being associated with increases in intracellular MnSOD activity (5, 19, 20, 22, 23) . Additionally, hyperoxic lung injury can be attenuated in transgenic mice expressing increased intracellular MnSOD in epithelial cells (29) .
Surfactant alterations in hyperoxic lung injury have been attributed to impairment of alveolar type II cells to synthesize surfactant of normal composition (13) as well as increased degradation of surfactant. MnSOD acting on the alveolar epithelial surface may have protected type II cell function in part, explaining the relatively minor surfactant changes seen in treated animals in this study.
Significant physiological deterioration including hypoxemia, decreased pulmonary compliance, and ventilation-perfusion abnormalities occurred with time despite treatment with MnSOD at all doses of the enzyme. There are several possible explanations for the lack of complete protection by the enzyme. First, it is possible that with continued exposure to hyperoxia, O 2 2 z production by the lung and inflammatory cells exceeds the extracellular antioxidant defenses despite the presence of MnSOD. Second, H 2 O 2 production may exceed the ability of catalase and glutathione peroxidase to de- 21 was associated with a severe metabolic acidosis (a group trend), whereas the early death of an animal receiving 1 mg·kg 21 · day 21 was not. Arterial oxygenation was significantly better than in untreated animals in all three treated groups, but there were no differences among the three doses of rhMnSOD. In contrast to the 3 mg·kg 21 · day 21 group, MAP, mean pulmonary arterial pressure, and oxygen delivery were not improved by treatment with rhMnSOD at 1 or 10 mg · kg 21 · day 21 . Thus a dosage ''window'' appears to provide significant protection without adverse effects.
This type of therapeutic window for dosing SOD has been observed by others in diverse models of oxidative stress and in different species (16, 17) . Low-dose drug failure can be explained by a lack of a threshold quantity of drug required for efficacy. High-end dosage failure is more difficult to explain, however, several theories are tenable (16, 17) . Excessive SOD may enhance lipid peroxidation by decreasing the free radical processes involved in terminating lipid peroxidation. Increased H 2 O 2 production at a site not prepared for attack by H 2 O 2 or a rapid burst of H 2 O 2 production that exceeds regional peroxidase defenses may result from excessive SOD administration.
Toxicity related to manganese is a possible but less likely explanation for the suboptimal outcome of the 10 mg·kg 21 · day 21 group. Manganese levels were not measured in this experiment, and the avidity of this enzyme complex for manganese under in vivo conditions is not known. Manganese can accumulate in mitochondria where it may interfere with oxidative phosphorylation. This effect could explain the acidosis and worse outcome at higher doses. The rhMnSOD, however, is very stable in vitro, and it is difficult to inactivate the enzyme chemically (T. Noonan, BoehringerIngelheim Pharmaceuticals, personal communication).
In summary, we have shown that aerosolized rhMnSOD provides physiological protection against injury from continuous exposure to 100% oxygen in baboons. The protection was most prominent at a dose of 3 mg·kg 21 · day 21 , and possible toxicity was seen with the 10 mg · kg 21 · day 21 dose. Further studies are needed to determine whether the mechanism of the protective effects is related to the catalytic activity of the enzyme and its localization in the lung. The data suggest that aerosolized MnSOD may be beneficial to patients with acute lung injury who are exposed to high concentrations of inspired oxygen for a prolonged period of time to prevent oxygen toxicity. The dose, however, would have to be chosen carefully to avoid potential drug toxicity.
